Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ pharmacology
Drug Resistance, Neoplasm
/ drug effects
Female
Follow-Up Studies
Humans
Hydroxyurea
/ pharmacology
Male
Middle Aged
Nitriles
Polycythemia Vera
/ drug therapy
Prognosis
Pyrazoles
/ therapeutic use
Pyrimidines
Salvage Therapy
Survival Rate
Myeloproliferative neoplasms
polycythemia vera
ruxolitinib
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
31
7
2019
medline:
20
9
2020
entrez:
31
7
2019
Statut:
ppublish
Résumé
Ruxolitinib was recently approved for the treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea based on data from the RESPONSE studies. This phase 3b, Expanded Treatment Protocol study (NCT02292446) of ruxolitinib for hydroxyurea-resistant/intolerant patients with polycythemia vera (
Identifiants
pubmed: 31359808
doi: 10.1080/10428194.2019.1636985
doi:
Substances chimiques
Antineoplastic Agents
0
Nitriles
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
Hydroxyurea
X6Q56QN5QC
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM